Source comparison
PT-141 Hypoactive Sexual Desire Complete Guide 2026: Comparison
PT-141 (bremelanotide) MC3R/MC4R agonist in hypothalamus 45–60 min On-demand (≤8 doses/month) Acquired, generalised HSDD in premenopausal women Nausea (40%), flushing, transient hypertension First-line for HSDD with normal hormone levels; requires precise timi
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC3R/MC4R agonist in hypothalamus
- 45–60 min
- On-demand (≤8 doses/month)
- Acquired, generalised HSDD in premenopausal women
- Nausea (40%), flushing, transient hypertension
- First-line for HSDD with normal hormone levels; requires precise timing and realistic outcome expectations
- Flibanserin (Addyi)
- 5-HT1A agonist / 5-HT2A antagonist
- 4–8 weeks
- Daily oral
- Premenopausal HSDD
- Hypotension, syncope (especially with alcohol), somnolence
- Better for secondary HSDD or serotonin-mediated desire suppression; contraindicated with alcohol
- Testosterone therapy
- Androgen replacement
- 2–6 weeks
- Daily (gel) or weekly (injection)
- HSDD with documented androgen deficiency
- Virilisation, lipid changes, cardiovascular risk
- Effective only when serum testosterone is clinically low; monitor levels quarterly
- Sildenafil (Viagra)
- PDE5 inhibitor (peripheral)
- 30–60 min
- On-demand
- Female sexual arousal disorder (off-label)
- Headache, flushing, visual disturbances
- Enhances genital blood flow but doesn't address desire deficit; ineffective for pure HSDD